Immunovant CTO Jay Stout sells $122,116 in shares

Immunovant's CTO, Jay S. Stout, transferred ownership of 3,809 shares of the company's common stock on October 7, 2026. The shares were sold to satisfy tax obligations related to the vesting of restricted stock units. The sale occurred between prices of $31.58 and $32.30 per share. The stock, currently valued at $30.47, has declined by around 9% over the past week, but has still risen by nearly 79% over the past year.

The sale comprised of 2,213 shares that became vested on October 1, 2026, and 1,596 shares that vested on October 2, 2026. These sales were not discretionary, as they were mandated by the issuer to cover tax withholding obligations. Following these transactions, Stout still holds 201,532 shares of Immunovant common stock. Immunovant recently announced that its drug candidate IMVT-1402 did not meet the primary endpoint in a clinical trial for cutaneous lupus erythematosus and will discontinue development of this drug for the specified indication.

Despite this setback, the company maintains a Buy rating with a price target of $41.00 from H.C. Wainwright, and an Overweight rating from Cantor Fitzgerald. Roivant Sciences, a related entity, reported a wider-than-expected first-quarter loss, but is preparing for an active second half of 2026.